生物制剂应用与CRSwNP内镜鼻窦手术率下降:纵向理赔数据库研究
基于Merative MarketScan数据库2016–2024年59,953例CRSwNP患者的回顾性研究,评估内镜鼻窦手术(ESS)与生物制剂处方率的时间趋势。结果显示ESS年率下降,生物制剂处方显著增加,2019年生物制剂引入后ESS率出现急剧下降。接受生物制剂者年龄更大且合并2型炎症共病(哮喘和过敏性鼻炎,p<0.001)。
要点
- CRSwNP患者ESS年率下降,生物制剂处方2016–2024年显著增加。
- 2019年生物制剂引入后ESS率出现急剧下降,生物制剂使用在2019–2020年大幅增加。
- 接受生物制剂者年龄更大,且合并哮喘和过敏性鼻炎(p<0.001)。
核心结论
- CRSwNP中生物制剂治疗近年显著增加,尤其见于年龄较大或合并2型炎症共病的患者。
- CRSwNP总体ESS使用率下降,ESS联合生物制剂治疗呈新兴现象但仍相对不常见。
研究设计与样本
- 回顾性研究,使用Merative MarketScan研究数据库2016–2024年数据,纳入59,953例CRSwNP患者。
- 通过回归和中断时间序列分析评估ESS与生物制剂处方率的季度和年度趋势。
主要发现
- ESS年率下降,生物制剂处方从2016至2024年显著增加,其中Dupilumab在生物制剂选择中占主导。
- 中断时间序列分析显示2019年生物制剂引入后ESS率急剧下降,生物制剂使用在2016–2024年持续增长且2019–2020年大幅增加。
- 接受生物制剂的患者年龄更大,合并哮喘和过敏性鼻炎(p<0.001 for both)。
临床怎么用
- 真实世界数据显示生物制剂在CRSwNP中的应用增加并伴随ESS使用率下降,可为治疗决策和医疗资源利用讨论提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real-world utilization of surgery and biologics remains incompletely characterized. OBJECTIVE: The aim of the study is to evaluate temporal trends in endoscopic sinus surgery (ESS) and biologic utilization in relation to 2019 Food and Drug Administration approval of biologics for CRSwNP. METHODS: Retrospective study of CRSwNP ESS and biologic prescription rates, patient demographics, and comorbidities within the Merative MarketScan Research database (2016-2024). Quarterly and annual trends were evaluated by regression and interrupted time series analyses. RESULTS: A total of 59,953 CRSwNP patients were included. Annual ESS rates declined, whereas biologic prescriptions increased markedly from 2016 to 2024. Dupilumab dominated among biologic alternatives. Interrupted time series analysis demonstrated a sharp decline in ESS rates with the 2019 introduction of biologics for CRSwNP, whereas biologic use grew continuously across 2016-2024 with a large increase in 2019-2020. Combination ESS and biologic treatment is growing but remains relatively infrequent. Patients receiving biologics were older and suffered from type 2 inflammatory comorbidities, such as asthma and allergic rhinitis (p<0.001 for both). CONCLUSION: In CRSwNP, biologic treatment has increased significantly in recent years, particularly in older patients or those with type 2 inflammatory comorbidities. Overall ESS utilization in CRSwNP has declined, and combination ESS and biologics are an emerging phenomenon. These figures reveal the extent of evolution in CRSwNP treatment induced by targeted medical therapies in real-world practice and serve as a foundation for healthcare utilization discussions.
引用
- Smith SS, Kaefer SL, Duvvuru H, et al. Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study. Int Forum Allergy Rhinol. 2026. PMID: 42643130. doi:10.1002/alr.70256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。